The Swiss pharmaceutical giant Roche Holding AG $RHHBY is set to pour $50 billion into the United States over the next five years. This substantial investment reflects a calculated move to enhance production and distribution channels amid shifting economic policies, particularly regarding potential tariff reductions on drug imports introduced during Donald Trump's presidency.